{"protocolSection": {"identificationModule": {"nctId": "NCT02304705", "orgStudyIdInfo": {"id": "14-0628-F3R"}, "organization": {"fullName": "University of Kentucky", "class": "OTHER"}, "briefTitle": "Sildenafil in Heart Failure With Reactive Pulmonary Hypertension", "officialTitle": "Sildenafil in Heart Failure With Reactive Pulmonary Hypertension", "acronym": "Sildenafil-HF"}, "statusModule": {"statusVerifiedDate": "2019-10", "overallStatus": "TERMINATED", "whyStopped": "Difficulty meeting enrollment goal", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-11-26", "studyFirstSubmitQcDate": "2014-12-01", "studyFirstPostDateStruct": {"date": "2014-12-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-11-20", "resultsFirstSubmitQcDate": "2019-03-12", "resultsFirstPostDateStruct": {"date": "2019-03-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-10-23", "lastUpdatePostDateStruct": {"date": "2019-11-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Maya Guglin", "investigatorTitle": "Professor, Clinical Faculty", "investigatorAffiliation": "University of Kentucky"}, "leadSponsor": {"name": "Maya Guglin", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether Sildenafil 20mg taken three times a day is effective in the treatment of Heart Failure with Reactive Pulmonary Hypertension. This is a double-blind, placebo controlled trial.", "detailedDescription": "Patients will be screened at the time of a diagnositic Right Heart Catheterization. Patients will be selected based on pressures measured during this procedure, current medications, and current symptoms. At baseline a 6 minute walk test and quality of life questionnaire will be administered. Medical records will be reviewed and results of recent testing will be recorded. Qualifying participants will be randomized to receive 90 days of either placebo or sildenafil 20 mg three times a day. Randomized patients will be followed for safety and efficacy by phone and as otherwise clinically indicated.\n\nAt the end of the 90 day treatment period, patients will be evaluated via 6 minute walk, quality of life questionnaire, and other diagnostic tests as clinically indicated. Primary outcome will be change in the 6 minute walk distance. Secondary outcomes will be based on clinically available results such as change in heart pressures measured by right heart catheterization and echocardiogram.\n\nAt the end of the treatment period, providers and patients will be unblinded in order to optimize further treatment.\n\nTo achieve statistical significance, 64 patients will be enrolled and randomized."}, "conditionsModule": {"conditions": ["Heart Failure With Reactive Pulmonary Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 33, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo three times per day, orally", "interventionNames": ["Drug: Placebo"]}, {"label": "Sildenafil", "type": "ACTIVE_COMPARATOR", "description": "Sildenafil 20 mg three times per day, orally", "interventionNames": ["Drug: Sildenafil"]}], "interventions": [{"type": "DRUG", "name": "Sildenafil", "description": "20 mg three times daily by mouth for 90 days", "armGroupLabels": ["Sildenafil"], "otherNames": ["Viagra"]}, {"type": "DRUG", "name": "Placebo", "description": "One capsule three times daily by mouth for 90 days", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Exercise Tolerance", "description": "In a controlled laboratory environment, participants will be asked to walk on a treadmill as fast as they can for 6 minutes. The test will be conducted at baseline and after 90 days of treatment. Data will be presented as the change in distance (in feet) walked in 6 minutes between baseline and treatment.", "timeFrame": "Baseline and 90 days"}], "otherOutcomes": [{"measure": "Change in Right Ventricular Function", "description": "Right ventricular function will be measured using tricuspid annular plane systolic excursion via two dimensional apical four-chamber echocardiography. Data will be collected at baseline and after 90 days of treatment", "timeFrame": "Baseline and 90 day"}, {"measure": "Change in Cardiac Output Relative to Body Surface Area (Cardiac Index)", "description": "cardiac output will be calculated by multiplying stroke volume by heart rate. Cardiac index will be calculated by dividing cardiac output (Liters/minute) by body surface area (meters squared). Data will be collected at baseline and the end of treatment (90 days)", "timeFrame": "Baseline and 90 days"}, {"measure": "Change in Pulmonary Vascular Resistance", "description": "Pulmonary vascular resistance will be determined by right heart catheterization. Data will be collected at baseline and at the end of treatment (90 days)", "timeFrame": "Baseline and 90 days"}, {"measure": "Change in Blood Pressure", "description": "through standard cuff method, participants will have blood pressure measured to determine systolic and diastolic blood pressure as well as mean arterial pressure. data will be collected at baseline and 90 days.", "timeFrame": "Baseline and 90 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Known chronic heart failure appropriately treated with Angiotensin converting enzyme (ACE) inhibitors and beta blockers, unless contraindicated or poorly tolerated\n* indication for right heart catheterization\n* pulmonary artery mean pressure \\>25 mmHg\n* pulmonary capillary wedge pressure \\> 15 mmHg\n* pulmonary vascular resistance \\> 3 Wood units\n\nExclusion Criteria:\n\n* hypersensitivity, allergy, or intolerable side effect to sildenafil\n* history of primary pulmonary hypertension, connective tissue disorder, severe chronic obstructive pulmonary disorder (COPD), pulmonary embolism, or left to right shunt\n* co-morbidities, limited exercise intolerance:\n\n  * morbid obesity (BMI \\>40)\n  * COPD with oxygen dependence\n  * severe peripheral vascular disease with intermittent claudication\n  * status post amputation of lower extremity at any level\n  * severe degenerative joint disease preventing normal walking", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Maya E Guglin, MD, PhD", "affiliation": "University of Kentucky", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Kentucky Medical Center", "city": "Lexington", "state": "Kentucky", "zip": "40536", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}]}, "referencesModule": {"references": [{"pmid": "27252841", "type": "DERIVED", "citation": "Guglin M, Rajagopalan N, Anaya P, Charnigo R. Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). Pulm Circ. 2016 Jun;6(2):161-7. doi: 10.1086/685548."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Placebo", "description": "Placebo three times per day, orally\n\nPlacebo: One capsule three times daily by mouth for 90 days"}, {"id": "FG001", "title": "Sildenafil", "description": "Sildenafil 20 mg three times per day, orally for 90 days"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants had baseline data collected. Only 10 Sildenafil and 12 Placebo had outcome data collects. Several were lost to follow up failures or withdrew either on their own or through PI recommendation.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Placebo three times per day, orally\n\nPlacebo: One capsule TID PO for 90 days"}, {"id": "BG001", "title": "Sildenafil", "description": "Sildenafil 20 mg three times per day, orally\n\nSildenafil: 20 mg TID PO for 90 days"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "23"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "13"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "20"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "29"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "33"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Exercise Tolerance", "description": "In a controlled laboratory environment, participants will be asked to walk on a treadmill as fast as they can for 6 minutes. The test will be conducted at baseline and after 90 days of treatment. Data will be presented as the change in distance (in feet) walked in 6 minutes between baseline and treatment.", "populationDescription": "Several participants were not analyzed for several reasons including death, failure to follow-up, PI withdrawal or subject withdrawal. In the Sildenafil group, 17 participants were consented while 10 were analyzed. In the Placebo group, 16 subjects were consented and 12 were analyzed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "feet", "timeFrame": "Baseline and 90 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "Placebo three times per day, orally\n\nPlacebo: One capsule TID PO for 90 days"}, {"id": "OG001", "title": "Sildenafil", "description": "Sildenafil 20 mg three times per day, orally\n\nSildenafil: 20 mg TID PO for 90 days"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "228", "spread": "174"}, {"groupId": "OG001", "value": "135", "spread": "22"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": ".052", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Right Ventricular Function", "description": "Right ventricular function will be measured using tricuspid annular plane systolic excursion via two dimensional apical four-chamber echocardiography. Data will be collected at baseline and after 90 days of treatment", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline and 90 day", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Cardiac Output Relative to Body Surface Area (Cardiac Index)", "description": "cardiac output will be calculated by multiplying stroke volume by heart rate. Cardiac index will be calculated by dividing cardiac output (Liters/minute) by body surface area (meters squared). Data will be collected at baseline and the end of treatment (90 days)", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline and 90 days", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Pulmonary Vascular Resistance", "description": "Pulmonary vascular resistance will be determined by right heart catheterization. Data will be collected at baseline and at the end of treatment (90 days)", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline and 90 days", "denomUnitsSelected": "Participants"}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in Blood Pressure", "description": "through standard cuff method, participants will have blood pressure measured to determine systolic and diastolic blood pressure as well as mean arterial pressure. data will be collected at baseline and 90 days.", "reportingStatus": "NOT_POSTED", "timeFrame": "Baseline and 90 days", "denomUnitsSelected": "Participants"}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse events were collected for 90 days from the date of consent until the drug protocol was complete.", "description": "Does not differ", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Placebo three times per day, orally\n\nPlacebo: One capsule TID PO for 90 days", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 0, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Sildenafil", "description": "Sildenafil 20 mg three times per day, orally\n\nSildenafil: 20 mg TID PO for 90 days", "deathsNumAffected": 1, "deathsNumAtRisk": 17, "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 0, "otherNumAtRisk": 17}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "There is a real risk that individuals presenting to the cardiology clinics will choose not to participate based on the physical exertion requirement."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Maya Guglin", "organization": "University of Kentucky", "email": "maya.guglin@uky.edu", "phone": "859-323-4738"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-04-04", "uploadDate": "2018-06-29T11:52", "filename": "Prot_SAP_000.pdf", "size": 679424}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006976", "term": "Hypertension, Pulmonary"}, {"id": "D000006973", "term": "Hypertension"}, {"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M10027", "name": "Hypertension, Pulmonary", "asFound": "Pulmonary Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068677", "term": "Sildenafil Citrate"}], "ancestors": [{"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058986", "term": "Phosphodiesterase 5 Inhibitors"}, {"id": "D000010726", "term": "Phosphodiesterase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000064804", "term": "Urological Agents"}], "browseLeaves": [{"id": "M292", "name": "Sildenafil Citrate", "asFound": "Core", "relevance": "HIGH"}, {"id": "M21320", "name": "Citric Acid", "relevance": "LOW"}, {"id": "M1837", "name": "Sodium Citrate", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M29332", "name": "Phosphodiesterase 5 Inhibitors", "relevance": "LOW"}, {"id": "M13629", "name": "Phosphodiesterase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "T382", "name": "Citrate", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Urol", "name": "Urological Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnCoag", "name": "Anticoagulants"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}